Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 1081 AL 1095

Dopaminergic neuronal integrity in parkinsonism associated with liver cirrhosis

Kim JM, Kim JS, Jeong SH, Kim YK, Kim SE, Kim SH, Kim Y.

Neurotoxicology. 2010 Aug;31(4):351-5. doi: 10.1016/j.neuro.2010.05.002. Epub 2010 May 8.

Retracted: Mechanism(s) of deep brain stimulation and insights into cognitive outcomes in Parkinson's disease

Naskar S, Sood SK, Goyal V, Dhara M.

Brain Res Rev. 2010 Oct 5;65(1):1-13. doi: 10.1016/j.brainresrev.2010.04.010. Epub 2010 May 10.

LRRK2 and Parkinson disease

Dächsel JC, Farrer MJ.

Arch Neurol. 2010 May;67(5):542-7. doi: 10.1001/archneurol.2010.79.

Ablation of a therapy-resistant posteroseptal accessory atrioventricular pathway: going for gold

McCann CJ, Gal B, Geelen P.

Acta Cardiol. 2010 Apr;65(2):269-70. doi: 10.2143/AC.65.2.2047067.

Molecular mechanisms of pathogenesis of Parkinson's disease

Shadrina MI, Slominsky PA, Limborska SA.

Int Rev Cell Mol Biol. 2010;281:229-66. doi: 10.1016/S1937-6448(10)81006-8.

Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease

Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A.

Mov Disord. 2010 May 15;25(7):805-22. doi: 10.1002/mds.22989.

The ParkinsonNet trial: design and baseline characteristics

Keus SH, Nijkrake MJ, Borm GF, Kwakkel G, Roos RA, Berendse HW, Adang EM, Overeem S, Bloem BR, Munneke M; ParkinsonNet Trial Study Group.

Mov Disord. 2010 May 15;25(7):830-7. doi: 10.1002/mds.22815.

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease

Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL; 228 Study Investigators.

Mov Disord. 2010 May 15;25(7):858-66. doi: 10.1002/mds.22890.

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study

Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W; German Competence Network on Parkinson's Disease.

Mov Disord. 2010 May 15;25(7):896-905. doi: 10.1002/mds.22974.

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations

Hersh BP, Earl NL, Hauser RA, Stacy M.

Mov Disord. 2010 May 15;25(7):927-31. doi: 10.1002/mds.23040.

Long-standing paraphilia induced by dopamine agonists in Parkinson's disease

Pineau F, Schüpbach M, Corvol JC, Flamand-Rouvière C, Vidailhet M, Roze E.

Mov Disord. 2010 May 15;25(7):963-5. doi: 10.1002/mds.23039.

The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease

Dobkin RD, Menza M, Bienfait KL, Gara M, Marin H, Mark MH, Dicke A, Tröster A.

J Neuropsychiatry Clin Neurosci. 2010 Spring;22(2):188-95. doi: 10.1176/jnp.2010.22.2.188.

Mitochondria and the link between neuroinflammation and neurodegeneration

Di Filippo M, Chiasserini D, Tozzi A, Picconi B, Calabresi P.

J Alzheimers Dis. 2010;20 Suppl 2:S369-79. doi: 10.3233/JAD-2010-100543.

Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury

Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, Nagley P.

J Alzheimers Dis. 2010;20 Suppl 2:S453-73. doi: 10.3233/JAD-2010-100321.

Mitochondrial iron metabolism and its role in neurodegeneration

Horowitz MP, Greenamyre JT.

J Alzheimers Dis. 2010;20 Suppl 2(Suppl 2):S551-68. doi: 10.3233/JAD-2010-100354.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias